Success Metrics

Clinical Success Rate
100.0%

Based on 42 completed trials

Completion Rate
100%(42/42)
Active Trials
3(6%)
Results Posted
71%(30 trials)

Phase Distribution

Ph phase_4
6
13%
Ph phase_2
10
21%
Ph phase_1
3
6%
Ph phase_3
25
52%

Phase Distribution

3

Early Stage

10

Mid Stage

31

Late Stage

Phase Distribution44 total trials
Phase 1Safety & dosage
3(6.8%)
Phase 2Efficacy & side effects
10(22.7%)
Phase 3Large-scale testing
25(56.8%)
Phase 4Post-market surveillance
6(13.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

97.7%

42 of 43 finished

Non-Completion Rate

2.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

48

all time

Status Distribution
Active(3)
Completed(42)
Terminated(1)
Other(2)

Detailed Status

Completed42
unknown2
Active, not recruiting2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
48
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (6.8%)
Phase 210 (22.7%)
Phase 325 (56.8%)
Phase 46 (13.6%)

Trials by Status

unknown24%
withdrawn12%
active_not_recruiting24%
completed4288%
recruiting12%

Recent Activity

Clinical Trials (48)

Showing 20 of 48 trialsScroll for more
NCT07626606

How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambia

Recruiting
NCT06824194Phase 3

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active Not Recruiting
NCT06824181Phase 3

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active Not Recruiting
NCT03621670Phase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
NCT04658914Phase 2

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

Completed
NCT01375647Phase 3

Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh

Completed
NCT04031846Phase 3

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Completed
NCT04344054Phase 2

Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine

Completed
NCT04010448Phase 3

A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India

Unknown
NCT00353366

To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

Completed
NCT03207750Phase 3

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Completed
NCT03602053Phase 2

Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia

Completed
NCT00263666Phase 2

A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

Completed
NCT02914184Phase 3

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Completed
NCT00969228Phase 4

Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants

Completed
NCT00489554Phase 3

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age

Completed
NCT00432380Phase 2

A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.

Completed
NCT00480324Phase 3

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

Completed
NCT01309646Phase 3

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Completed
NCT02096263Phase 3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
48